TNSN08064A1 - Albumin fusion proteins - Google Patents
Albumin fusion proteinsInfo
- Publication number
- TNSN08064A1 TNSN08064A1 TNP2008000064A TNSN08064A TNSN08064A1 TN SN08064 A1 TNSN08064 A1 TN SN08064A1 TN P2008000064 A TNP2008000064 A TN P2008000064A TN SN08064 A TNSN08064 A TN SN08064A TN SN08064 A1 TNSN08064 A1 TN SN08064A1
- Authority
- TN
- Tunisia
- Prior art keywords
- fusion proteins
- albumin fusion
- nucleic acids
- vectors
- host cells
- Prior art date
Links
- 102000009027 Albumins Human genes 0.000 title abstract 6
- 108010088751 Albumins Proteins 0.000 title abstract 6
- 102000037865 fusion proteins Human genes 0.000 title abstract 6
- 108020001507 fusion proteins Proteins 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 239000013598 vector Substances 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 | |
| PCT/US2006/029391 WO2007021494A2 (en) | 2005-08-12 | 2006-07-31 | Albumin fusion proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN08064A1 true TNSN08064A1 (en) | 2009-07-14 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2008000064A TNSN08064A1 (en) | 2005-08-12 | 2008-02-11 | Albumin fusion proteins |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (ja) |
| JP (1) | JP2009504157A (ja) |
| KR (1) | KR20080071119A (ja) |
| AU (1) | AU2006280312A1 (ja) |
| BR (1) | BRPI0614761A2 (ja) |
| CA (1) | CA2618476A1 (ja) |
| EC (1) | ECSP088262A (ja) |
| IL (1) | IL189246A0 (ja) |
| MA (1) | MA29836B1 (ja) |
| MX (1) | MX2008001865A (ja) |
| NO (1) | NO20081233L (ja) |
| TN (1) | TNSN08064A1 (ja) |
| WO (1) | WO2007021494A2 (ja) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| EP1278544A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| EP2277910A1 (en) | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PL1729795T3 (pl) | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| EP2474318A1 (en) | 2006-06-07 | 2012-07-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| KR20090064453A (ko) * | 2006-09-14 | 2009-06-18 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| EP2450366A1 (en) | 2007-01-30 | 2012-05-09 | Epivax, Inc. | Regulatory t cell epitopes, compositions and uses thereof |
| EP2305309A2 (en) | 2008-06-13 | 2011-04-06 | Proyecto de Biomedicina Cima, S.L. | Conjugates for the administration of biologically active compounds |
| JP2012515222A (ja) | 2009-01-16 | 2012-07-05 | テバ ファーマシューティカル インダストリーズ リミテッド | 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤 |
| JP5936112B2 (ja) | 2009-02-11 | 2016-06-15 | アルブミディクス アクティーゼルスカブ | アルブミン変異体及び複合体 |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| WO2011028229A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor ix compositions and methods of making and using same |
| EP2493921B1 (en) * | 2009-10-30 | 2018-09-26 | Albumedix Ltd | Albumin variants |
| KR20130070576A (ko) | 2010-04-09 | 2013-06-27 | 노보자임스 바이오파마 디케이 에이/에스 | 알부민 유도체 및 변이체 |
| US9238080B2 (en) | 2010-05-21 | 2016-01-19 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| WO2012118042A1 (ja) * | 2011-02-28 | 2012-09-07 | 独立行政法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
| MX353816B (es) | 2011-05-05 | 2018-01-30 | Albumedix As | Variantes de albumina. |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9486507B2 (en) | 2011-06-10 | 2016-11-08 | Biogen Ma Inc. | Pro-coagulant compounds and methods of use thereof |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| CA2811250C (en) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methods for treating hcv |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| GB2506086A (en) | 2011-10-21 | 2014-03-19 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
| US20140315817A1 (en) | 2011-11-18 | 2014-10-23 | Eleven Biotherapeutics, Inc. | Variant serum albumin with improved half-life and other properties |
| PT2804623T (pt) | 2012-01-12 | 2019-11-18 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos do fator viii e suas utilizações |
| LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
| CA2864126A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| PL2825556T3 (pl) | 2012-03-16 | 2018-10-31 | Albumedix A/S | Warianty albuminy |
| EP4079316A1 (en) | 2012-06-08 | 2022-10-26 | Bioverativ Therapeutics Inc. | Procoagulant compounds |
| JP2015525222A (ja) | 2012-06-08 | 2015-09-03 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | キメラ性凝固因子 |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| BR112015000267B1 (pt) | 2012-07-11 | 2023-01-24 | Bioverativ Therapeutics Inc. | Proteínas quiméricas, e composição farmacêutica |
| EP2908847B1 (en) | 2012-10-18 | 2022-03-30 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| GB2512156A (en) | 2012-11-08 | 2014-09-24 | Novozymes Biopharma Dk As | Albumin variants |
| FI2956477T4 (fi) | 2013-02-15 | 2024-04-24 | Bioverativ Therapeutics Inc | Optimoitu tekijä viii:n geeni |
| EP2956002B1 (en) | 2013-02-16 | 2017-09-06 | Albumedix A/S | Pharmacokinetic animal model |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| NZ713904A (en) | 2013-06-28 | 2022-02-25 | Bioverativ Therapeutics Inc | Thrombin cleavable linker with xten and its uses thereof |
| TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| EP3048899B1 (en) | 2013-09-25 | 2021-09-08 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| EP3065769A4 (en) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Procoagulant fusion compound |
| CN116621991A (zh) | 2014-01-10 | 2023-08-22 | 比奥贝拉蒂治疗公司 | 因子viii嵌合蛋白及其用途 |
| EP3160478A4 (en) | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
| DK3207130T3 (da) | 2014-10-14 | 2019-11-11 | Halozyme Inc | Sammensætninger af Adenosin Deaminase-2 (ADA2), varianter deraf og fremgangsmåder til anvendelse af samme |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| EP3337816B1 (en) | 2015-08-20 | 2024-02-14 | Albumedix Ltd | Albumin variants and conjugates |
| WO2017059231A1 (en) | 2015-10-02 | 2017-04-06 | Silver Creek Pharmaceuticals, Inc. | Bi-specific therapeutic proteins for tissue repair |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| PL3411478T3 (pl) | 2016-02-01 | 2022-10-03 | Bioverativ Therapeutics Inc. | Geny zoptymalizowanego czynnika VIII |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
| JP2020500306A (ja) | 2016-11-04 | 2020-01-09 | オーフス ウニベルシテット | 新生児Ｆｃ受容体の過剰発現により特徴づけられる腫瘍の同定と治療 |
| MX2019006446A (es) | 2016-12-02 | 2019-12-11 | Bioverativ Therapeutics Inc | Métodos para inducir tolerancia inmunológica a factores de coagulación. |
| EP3548066A1 (en) | 2016-12-02 | 2019-10-09 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| MA47163A (fr) | 2016-12-16 | 2019-11-06 | Biogen Ma Inc | Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé |
| KR20190112763A (ko) | 2017-01-31 | 2019-10-07 | 바이오버라티브 테라퓨틱스 인크. | 인자 ix 융합 단백질 및 이의 제조 및 사용 방법 |
| EP3612558A1 (en) * | 2017-04-20 | 2020-02-26 | Novo Nordisk A/S | Methods of purification of albumin fusion proteins |
| SG11202000764RA (en) | 2017-08-09 | 2020-02-27 | Bioverativ Therapeutics Inc | Nucleic acid molecules and uses thereof |
| US20210038744A1 (en) | 2018-02-01 | 2021-02-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor viii |
| SG11202010767SA (en) | 2018-05-18 | 2020-11-27 | Bioverativ Therapeutics Inc | Methods of treating hemophilia a |
| BR112021002017A2 (pt) | 2018-08-09 | 2021-05-11 | Bioverativ Therapeutics Inc. | moléculas de ácido nucleico e usos das mesmas para terapia genética não viral |
| JP2022514465A (ja) | 2018-12-06 | 2022-02-14 | バイオベラティブ セラピューティクス インコーポレイテッド | 第ｉｘ因子を発現するレンチウイルスベクターの使用 |
| TW202126284A (zh) | 2019-09-30 | 2021-07-16 | 美商百歐維拉提夫治療公司 | 慢病毒載體配製物 |
| WO2022030580A1 (ja) * | 2020-08-06 | 2022-02-10 | 国立大学法人宮崎大学 | 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途 |
| WO2024080306A1 (ja) * | 2022-10-11 | 2024-04-18 | Ｊｃｒファーマ株式会社 | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2277910A1 (en) * | 2001-12-21 | 2011-01-26 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2005003296A2 (en) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PL1729795T3 (pl) * | 2004-02-09 | 2016-08-31 | Human Genome Sciences Inc | Białka fuzyjne albuminy |
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 EP EP06813242A patent/EP1924596A4/en not_active Withdrawn
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Application Discontinuation
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 CA CA002618476A patent/CA2618476A1/en not_active Abandoned
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/en active Application Filing
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2008001865A (es) | 2008-04-15 |
| CA2618476A1 (en) | 2007-02-22 |
| EP1924596A4 (en) | 2009-07-29 |
| IL189246A0 (en) | 2008-08-07 |
| AU2006280312A1 (en) | 2007-02-22 |
| BRPI0614761A2 (pt) | 2009-05-19 |
| EP1924596A2 (en) | 2008-05-28 |
| ECSP088262A (es) | 2008-05-30 |
| JP2009504157A (ja) | 2009-02-05 |
| NO20081233L (no) | 2008-05-09 |
| WO2007021494A2 (en) | 2007-02-22 |
| WO2007021494A3 (en) | 2007-07-26 |
| MA29836B1 (fr) | 2008-10-03 |
| KR20080071119A (ko) | 2008-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08064A1 (en) | Albumin fusion proteins | |
| MX2009002816A (es) | Proteinas de fusion de albumina. | |
| WO2007146038A3 (en) | Albumin fusion proteins | |
| WO2005077042A3 (en) | Albumin fusion proteins | |
| WO2005003296A3 (en) | Albumin fusion proteins | |
| WO2003060071A3 (en) | Albumin fusion proteins | |
| WO2001079443A3 (en) | Albumin fusion proteins | |
| WO2003059934A3 (en) | Albumin fusion proteins | |
| WO2003030821A3 (en) | Albumin fusion proteins | |
| HK1205193A1 (en) | Recombinant n-glycosylated proteins from procaryotic cells n- | |
| EA201690946A1 (ru) | Мутанты fgf21 и их применение | |
| EA201171220A1 (ru) | Мутанты fgf21 и их применение | |
| EA201990619A1 (ru) | Fgf21 мутанты и их применение | |
| WO2005063820A3 (en) | Il-7 fusion proteins | |
| IN2012DN02981A (ja) | ||
| MX2009004243A (es) | Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal. | |
| WO2006017355A3 (en) | Improved aprotinin variants | |
| WO2002097110A3 (en) | TUMOR ENDOTHELIAL MARKER 7α MOLECULES AND USES THEREOF | |
| WO2006110367A3 (en) | Methods and compositions for mycoplasma toxins |